Increased Incidence of Severe Adverse Events in Non-Small Cell Lung Cancer Patients with Previous Tuberculosis Episode Treated with PD-1 Inhibitors
- Author:
Zhang HUI
1
;
Yuan JINFENG
;
Xu YUANYUAN
;
Yang MENGJIE
;
Lyu JIALIN
;
Yang XINJIE
;
Sheng SHUYAN
;
Qian ZHE
;
Wang QUNHUI
;
Pang YU
;
Hu YING
Author Information
- Keywords: Lung cancer; Tuberculosis; Immune checkpoint inhibitors; Adverse events; PD-1
- From: Biomedical and Environmental Sciences 2024;37(7):785-789
- CountryChina
- Language:Chinese
- Abstract: Lung cancer is the top cause of cancer deaths globally.Advances in immune checkpoint inhibitors(ICIs)have transformed cancer treatment,but their use in lung cancer has led to more side effects.This study examined if past pulmonary tuberculosis(TB)affects ICIs'effectiveness and safety in lung cancer treatment.We reviewed lung cancer patients treated with ICIs at Beijing Chest Hospital from January 2019 to August 2022.We compared outcomes and side effects between patients with and without prior TB.Of 116 patients(40 with TB history,76 without),prior TB didn't reduce treatment effectiveness but did increase severe side effects.Notably,older patients(≥65 years)faced a higher risk of severe side effects.Detailed cases of two patients with severe side effects underscored TB as a risk factor in lung cancer patients receiving ICIs,stressing the need for careful monitoring and personalized care.
